eFT226-(zotatifin)

first-in-class eIF4A RNA helicase inhibitor

in clinical dev. for solid tumors (Ph. I, IV QW)

from optimization of a natural product

J. Med. Chem., May 29, 2020

eFFECTOR Therapeutics, San Diego, CA

eFT226 (zotatifin) is a beautiful natural product-derived molecule that inhibits the RNA helicase eIF4A by forming a ternary complex between it, eIF4A, and polypurine RNA. Interestingly, the stability of the…


 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.